Mesotheliomas 101

Actos and Bladder Cancer : BC is a disease of the environment and age . Populations are increasing in number, and they are growing old as well., . Since more people are living longer, more are at potential risk. Furthermore, the changing environments in developed and developing countries are causing more carcinogen concentration than can be associated to genesis of BC. Several carcinogens have been correlated to BC carcinogenesis.However, it has been proposed that other environmental factors could affect the incidence on urothelial tumors. In fact, as for many other cancers, molecular researchers try to establish genetic alterations linked to carcinogenesis that could justify genetic predisposition.

Cancer is a major public health problem. At the end of the twentieth century, more than 930,000 people died of cancer every year in 15 member countries of the European Union (EU) (Coleman et al. 2003). Using population projections, if the age-specific death rates remain constant, the absolute number of cancer deaths in 2015 will increase to 140,500 (Boyle and Ferlay 2005). BC is a worldwide health problem. In 2006 in Europe, there were an estimated 104,400 incident cases of BC

More information on Actos and Bladder Cancer

diagnosed (82,800 in men and 21,600 in women) that represent a 6.6% of the total cancers in men and 2.1% in women. The estimated ratio by gender was 3.8:1, respectively. In men BC was the fourth most common cancer. Bladder cancer repre­sents a 4.1% of total deaths for cancer in men and 1.8% of total deaths in women (Ferlay et al. 2007). In the EU overall (27 countries), BC mortality rates were stable up to early 1990s, and declined, thereafter, by 16% in men and 12% in women, to reach values of 6 and 1.3/100,000, respectively, in the early years of the present decade. The only countries without declining mortality are Croatia and Poland in both sexes, Romania in men, and Denmark in women. This documented and quanti­fied reduction in BC mortality seems related to decrease in tobacco smoking, while its relationship with other risk factors remains controversial (Ferlay et al. 2008).In the United States, it is estimated that about 1.4 million new cases of cancer was diagnosed in 2008. Cancers of the prostate and breast are the most frequently diagnosed cancers in men and women, respectively, followed by lung and colorec­tal cancers in both men and in women. The fourth most common among men is the urinary BC. The 5-year relative survival rate for BC is 81% among whites and 65% among African-Americans (AAs) (taking the normal life expectancy into consider­ation) with an absolute difference of 16%. The survival rates for BC combined with certain site-specific cancer have improved significantly since the 1970s—being 74% during 1975-1977, 78% during 1984-1986, and 81% during 1996-2003.

Information from other sources on Actos and Bladder Cancer

Contrary to this data, the prevalence of BC among Native Americans/Alaskan Natives (NA/AN) is generally considered to be low. Despite this low incidence, NA/AN men and women seem to be at relatively greater risk of dying from BC, once it has been diagnosed (Watson and Sidor 2008).Tobacco use is a major preventable cause of death, and especially involved in BC carcinogenesis. The year 2004 marks the anniversary of the release of the first Surgeon General’s report on Tobacco and Health, which initiated a decline in per capita cigarette consumption in the United States (Jemal et al. 2008).

In Egypt, where BC has always been related to bilharziasis, a significance decline of the relative frequency of BC was observed from 27.63% in the old series to 11.7% in the recent series. Bilharzias association dropped from 82.4% to 55.3% and there was a significant increase of transitional cell carcinoma from 16% to 65%, while squamous cell carcinoma was less frequent—from 76% to 28%. Intimately related to this, there was an increase in the median age of patients from 47 to 60 years. The decline in the frequency of BC is related to a decline in bilhar- zias egg positivity in the specimen, and this suggests a better control of the endemic disease in rural population. This trend of less association with bilharzias has changed the clinical and pathological characteristics of BC diagnosed, with signifi­cant predominance of transitional cell carcinoma and an increase in the age of patients, a pattern more similar to that in western series (Gouda et al. 2007).

The incidence and mortality rates associated with BC vary by country, ethnicity, gender, and age. For indeterminate causes, the AAs have only half the risk of white European Americans, but overall, the survival seems to be worse among the primer group. The higher incidence in European Americans is limited to superficial tumors, both groups having a similar risk of invasive tumor (Kirkali et al. 2005).

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Actos and Bladder Cancer: NAVIGATING APPOINTMENTS

Calls initially made to a urology office or clinic are triaged by the scheduling staff who are trained to inquire about the current stage of your workup for your bladder cancer. It is most helpful to have a working knowledge of the tests and diagnoses you have already been given to best facilitate this process. The staff will schedule your initial appoint­ment and mail you all necessary instructions before your appointment. After your initial appointment, subsequent appointments may often be arranged by the individual team members’ staff over the phone. If at the initial ap­pointment it is determined you should have a consultation with another team member (e.g., medical oncologist or radiation oncologist), that appointment is often arranged for you on die day of your initial consultation with the uro- logic oncologist-—-before you leave the clinic if you choose. Therefore having your schedule available allows you to ef­ficiently make these arrangements without conflict.

More information on Actos and Bladder Cancer

FINANCIAL IMPLICATIONS OF TREATMENT/INSURANCE CLEARANCE

You probably never planned on getting diagnosed with bladder cancer. There is no convenient time to get this dis­ease, and the diagnosis alone can be difficult to manage. You will need to take time off from work and other duties for your surgery and possibly for other treatment after­ward. It is helpful then to “get your ducks in a row” early on. Finding out how much sick leave you have, short-term disability coverage, copayment information, prescription coverage, and other medical expense issues is helpful to plan for die changes this will have on your budget. Your insurance company may require referrals to be obtained to see certain specialists, to get tests done, to get surgery au­thorized, as well as to obtain other treatments. If you need help with these things, ask for a social worker to assist you. Financial coordinators are available in the clinic. They will work with you to help you navigate the financial aspect of this process.

Some treatments may be recommended that involve par­ticipation in a clinical trial. Usually, a research nurse will as­sist you with navigating the financial aspects of this line of therapy and can provide much of that information for you.

Information from other sources on Actos and Bladder Cancer

Financial support services are not well advertised. It re­quires you to take the initiative to ask about them rather than waiting for someone to tell you about them. Be asser­tive and do this for yourself That’s why these programs ex­ist. Money is the primary reason family members get into arguments. Avoid this up front by discussing the issue and planning a budget. Be proactive in asking to meet with the social worker to discuss what support services are available for you as well.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

Actos and Bladder Cancer

Actos and Bladder Cancer : An intravenous pyelogram (IVP) is an X-ray study that shows the general outline of the kidneys and better detail of the collecting system than an ultra­sound. X-ray contrast is given to the patient intra­venously. The kidneys then filter and concentrate the contrast, creating an image on an X-ray taken a few minutes after the injection is given. A small tumor or stone inside the collecting system can be seen as a dark spot inside the collecting system. Historically, the IVP was a common test to evaluate upper tracts. However, due to the decreased cost of CT scans and the increased availability, it has largely been replaced by CT scanning.

CT scanners use X-rays to create a detailed image of the internal organs. The scanner takes many X-rays at once and uses a computer to combine all of the images into the one picture that you see. When getting a CT scan of the kidneys, the patient is usually scanned three times. The first scan is per­formed without contrast and will reveal any kidney stones. The second scan is performed with contrast, which helps to show tumors in the kidneys. The third scan is obtained a few minutes later, after the kidney has had time to process the contrast. The contrast fills the collecting system similar to the IVP but with greater detail. A CT scan is very good for seeing tumors in both the kidneys and the col­lecting system. In addition to the ability to see the kidneys and ureters better, the CT scan allows for visualization of the entire abdomen and lymph nodes, helping to identify metastases or unrelated diseases. Over the last several years, the cost of CT scans has come down, and the availability of scan­ners to patients has increased, making the CT scan the most common upper tract study. As with the IVP test, CT scans meant to examine the kidneys

For more information on Actos and Bladder Cancer follow us on our RSS Feeds.

Although ureteroscopy is not technically an “upper tract study,” it gives us the most definitive examina­tion. It is similar to cystoscopy but uses a smaller scope. In the operating room or well-equipped office, the ureteroscope is carefully passed into the ureter as it opens into the bladder. This allows the urologist to see the inside of the ureter. It is gently passed all of the way up the ureter into the kidney. Like cys­toscopy, there are both rigid and flexible uretero- scopes. The flexible scope allows doctors to see all or most of the deep corners of the collecting system within the kidney. Biopsies of any suspicious areas can be taken and sent to pathology for analysis. Although ureteroscopy provides the best view of the collecting system, it usually requires anesthesia, and there is some small risk of damage to the kidney or ureter; thus, it is usually reserved for those patients who have had an abnormal upper tract study.

Information from other sources on Actos and Bladder Cancer

Cysview (hexaminolevulinate hydrochloride, GE health­care) has recently been approved as an optical imaging agent for use in the cystoscopic detection of non-muscle invasive papillary bladder cancer among patients sus­pected or known to have lesion(s) on the basis of prior cystoscopy. When used in combination with blue light (fluorescence) cystoscopy (Karl Storz D-Light C Pho­todynamic Diagnostic [PPD] system) it identified at least 1 more noninvasive papillary bladder tumor than rou­tine cystoscopy in about one third of the patients with such tumors. It is also useful in detecting carcinoma in situ, identifying 28% more patients with carcinoma in situ than standard cystoscopy.

Urine cytology is commonly used to screen for bladder cancer in patients who have hematuria as well as to monitor for recurrences in patients who are being treated for bladder cancer. Overall, urine cytology is able to detect 40% to 60% of bladder cancers, but the ability of cytology to detect a tumor varies depending on the grade, stage, and location of the tumor. In low-grade, low- stage tumors, cytology will detect only 25% to 40% of the tumors. It will perform better as the grade and stage of the tumor increase, with the best detection rate being for carcinoma in situ. Cytology detects approximately 90% of cases of carcinoma in situ.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Actos and Bladder Cancer : Ureteral injury may occur when a tumor covers the ureter in the bladder. The ureter may be obscured by a bladder tumor, and the urologist may inadvertently resect it along with the tumor. In general, cutting current to remove a bladder tumor does not usually lead to long lasting problems as compared to cauterization, which is more likely to cause permanent blockage or obstruction of the ureter. If the urologist is working in the area of the ureter, he should avoid cauterization as much as possible. He may ask the anesthetist to inject an intravenous coloring agent which will turn the urine blue

and allow visualization of the ureter. If he knows a ureter may be in jeopardy, he may insert a stent (a small plastic tube that traverses the ureter) for several weeks to allow the ureter to heal in an open fashion.

Urethral injury is infrequent and is almost always in males. A stricture or narrowed area of the urethra may result from irritation or injury from the resectoscope pressing on the urethra. Individuals that develop strictures complain of difficulty urinating, experiencing a slow or split stream. Strictures are usually readily handled with a number of urologic procedures.

More information on Actos and Bladder Cancer

Bladder tumor “seeding” may occur during the procedure. As the tumors are resected, cancer cells are released into the irrigant which fills the bladder. These cells may implant in other areas of the bladder traumatized during the procedure. It should be understood that the bladder is generally filled with urine, and tumor cells can naturally implant at other locations even without surgery. Implantation can be lessened during surgery by avoiding injury to other bladder areas and by the use of adjuvant intravesical chemotherapy. There have been numerous studies over the past decade showing a number of chemotherapy agents can be effective in decreasing initial tumor recurrence, possibly by preventing seeding. Reduction in recurrence may however be short lived. Previously, it was common practice to obtain multiple random bladder biopsies at the time of initial tumor resection. This was recommended to rule out the possibility of hidden CIS. Understanding these biopsy sites may increase the possibilities of tumor recurrence by tumor seeding, biopsies are now often limited to areas adjacent to the tumors removed and suspicious appearing areas only. CIS can be ruled out by using cytology, or by obtaining biopsies during future cystoscopy after the tumor has already been removed. When dealing with low grade tumors, random biopsies of the bladder will rarely show cancer.^[1]

Information from other sources on Actos and Bladder Cancer

After your procedure, depending on the level of anesthesia and the extent of surgery, you will be brought either to the recovery room or back to the area where you were first prepared for your procedure. You will be released to home only when you have fully recovered from you anesthetic and are doing well.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Actos and Bladder Cancer : The recurrence rate for superficial bladder cancer can be as high as 60-90%. Recurrences can cause bleeding and other difficulties and are best handled sooner rather than later. In addition, depending on the initial tumor grade and stage, progression to a more serious form of bladder cancer is an ongoing concern. Surveillance cystoscopy is therefore recommended.

More information on Actos and Bladder Cancer

Cystoscopy is still the best means to check for recurrent disease. It is however, an invasive procedure and should be accomplished only as often as required. For solitary, low grade, non invasive disease, follow up cystoscopy can be accomplished with the flexible cystoscope if available. If negative at three months, further cystoscopic exams can be done yearly and eventually lengthened even further. For those with multiple tumors, large tumors, high grade tumors or those who also have CIS, frequent cystoscopies, initially every three months are called for. As long as there are no recurrences, the time between cystoscopies can be lengthened. Cytology can also be utilized to reduce the number of cystoscopies. If recurrence or progression does occur, heightened scrutiny is again called for.

Information from other sources on Actos and Bladder Cancer

BESIDES A BLADDER TUMOR, MY CT SCAN INDICATED MY KIDNEY IS SWOLLEN BECAUSE OF A BLOCKAGE OF MY URETER. DID THE BLADDER TUMOR CAUSE THIS BLOCKAGE AND DOES IT MEAN MY PROGNOSIS IS WORSE?

There are many medical conditions that may result in hydroureteronephrosis (swelling of the kidney and ureter), having nothing to do with bladder cancer. It is also true large bladder tumors may grow into the wall of the bladder and cause ureteral obstruction at the level of the bladder. When this is found, the prognosis is usually poor, as the tumors involved are usually high grade and deeply invasive. On occasion, a superficial low grade tumor may grow directly into the ureteral opening. In this situation, prognosis is not generally any worse, as the blockage has not occurred from an invasive tumor.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Actos and Bladder Cancer : The urinary system (Figure i-i) is very important and has a pretty tough job to do in everyone’s body. It filters your blood and produces waste products in the form of urine. More importantly, it allows you to store urine until it is convenient to urinate. Just think, if we couldn’t store urine, then we would constantly leak waste products. This would make life very difficult and get in the way of things we do during the course of a normal day. The human urinary system is made up of the kidneys, ureters, bladder, and urethra. Men have a prostate gland in addition to the previously mentioned components.

More information on Actos and Bladder Cancer

Your kidneys are two bean-shaped organs that reside in the rear of your abdomen, just under the diaphragm on the left and below the liver on your right side. The kidneys filter blood and produce urine. They are extremely important to life and work extremely hard to filter waste from your bloodstream. Just imagine, the kidneys filter approximately 20 percent of your blood each minute. Although most people have two kidneys, some individuals have one and do just fine. The kidneys function independently, and when one is not working as well, the other compensates and filters more blood. In addition to filtering blood and producing urine, your kidneys help to regulate your blood pressure. They produce special hormones and control the salt and water balance in your body. Normally, the kidneys do not release blood cells into urine. This is why it’s important to be evaluated by a doctor if you have blood in your urine.

Information from other sources on Actos and Bladder Cancer

URETERS

After urine is formed by the kidneys, special nerves and muscles in the renal pelvis propel urine downward into the ureters. The ureters are small tubes, very much like the renal pelvis, that allow passage of urine from die kidneys down to the bladder. They function as drainage pipes for the kidney. The ureters have nerves and layers of muscle that propel urine to the bladder. There is so much that your body does that you may not realize. Like the renal pelvis, the ureters are also lined with transitional cells serving as a continuation of die uxothelium.

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Actos and Bladder Cancer :

BLADDER

The ureters connect to the bladder, which is a muscular, balloon-lilce structure in the pelvis. The bladder functions as the storage unit of the urinary system. It can hold upward of 500-600 mL (2 cups) of urine. Hie bladder is very thick and elastic with multiple layers .

An inner layer made up of transitional cells forming the urothelium; under this lies a thin layer (the lamina propria), with blood vessels supplying the bladder; and finally a thick muscular layer that contracts to empty your bladder. There is a layer of fat surrounding the muscular layer.

The bladder expands in relation to the amount of fluid inside of it Bladder contraction is under complex control by your central nervous system. When your bladder contracts during urination, urine passes though the urethra before leaving your body. The inner cells, closest to the bladder, are transitional cells, whereas the cells closest to the outside of the body are squamous cells resembling skin. Although the urethra has different lengths in men and women, it functions the same. In men, the urethra passes through the prostate gland near the bladder.

More information on Actos and Bladder Cancer

PROSTATE

The prostate, a walnut-sized organ that lies at the base of the bladder in men, plays a role in male fertility. Along with the seminal vesicles, the prostate gland produces fluid that helps sperm after ejaculation. Although the urethra passes through the prostate, the gland itself does not add much, if anything, to the volume of urine that reaches the bladder. As the urethra passes through the prostate, it is lined by transitional cells comprising the urothelium. Therefore, tilings that affect the urothelium can affect the prostate as well. This is very important when it comes to staging bladder cancer.

The urethra is a hollow tube lined with transitional cells at its beginning that connects the bladder to the outside world. The structure of the urethra is different in men and women. The urethra is short in women and is much longer in men due to the presence of the penis. The cells lining the

urethra change along its length. The inner cells, closest to the

Information from other sources on Actos and Bladder Cancer

Our use of the term or terms Actos and Bladder Cancer is for descriptive purposes only. There is no relationship between the owners of this website and the maker of the product discussed in this post. Our use of the words Recall, Class Action Lawsuit and other similar words related to an event do not necessarily mean that this event has occurred. Refer to the website of the United States Food and Drug Administration for information on drug or medical device recalls. If a Class Action Lawsuit is formed in relation to the product discussed in this post we will provide that information at the time the Class Action is formed. A Class Action Lawsuit is not required to exist for you to file a lawsuit if you have been injured by the product discussed in this post.

To keep up to date on Actos and Bladder Cancer visit our site often.

http://www.seedol.com

Actos and Bladder Cancer12/20/2011: The neurovascular bundles which run adjacent and adherent to the prostate can be pushed aside as the bladder and prostate are removed. This is more technically difficult compared to the standard non-nerve sparing approach. Sparing the nerves is not always possible even with the best effort. If the individual has questionable erections prior to the surgery, a nerve sparing procedure rarely leads to preservation of erections and therefore is not warranted. Extensive bladder cancer may encroach on the prostate, making a nerve sparing procedure extremely difficult if not impossible.

For more information on Actos and Bladder Cancer follow us on our RSS Feeds.

Our use of the Terms Actos Litigation , Actos FDA Recall is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Actos.Actos is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection with Takeda Pharmaceutical Company Limited.

http://www.seedol.com

Actos Attorney12/15/2011: The elderly, frail individuals with multiple coexisting chronic illnesses, individuals that are weakened through mahiutrition or who have compromised immunity all would face substantially increased risk of complications from standard chemotherapy regimens for bladder cancer. Unfortunately, cisplatin is toxic to kidneys, and many individuals with bladder cancer have compromised kidney function which effectively rules out the use of platinum based chemotherapy. Other treatment regimens exist and are being worked on for these individuals, but none show the efficacy of the standard therapy which includes cisplatin.

For more information on Actos Attorney follow us on our RSS Feeds.

Our use of the Terms Actos Settlements, Actos and Bladder Cancer is not intended to imply or insinuate that there is any relationship or connection between Best Legal Source and the maker of Actos. Actos is a trademark of its manufacturer, Takeda Pharmaceutical Company Limited. Best Legal Source is not the maker of Actos nor do we have any connection with Takeda Pharmaceutical Company Limited.

http://www.seedol.com